风湿病学2期与3期随机对照试验的疗效结局比较
该系统荟萃分析纳入所有研究靶向改善病情抗风湿药的随机双盲对照试验,比较类风湿关节炎和银屑病关节炎中2期与3期试验的ACR20应答。类风湿关节炎中2期试验系统性高估3期结果(OR 1.39,95%CI 1.25-1.57,P<0.001),银屑病关节炎数据相似但无统计学意义;纳入标准差异 largely 解释疗效差异。
要点
- 类风湿关节炎2期试验ACR20应答系统性高估3期结果。
- 银屑病关节炎2期与3期ACR20差异无统计学意义。
- 纳入标准差异 largely 解释2期与3期疗效差异。
核心结论
- 类风湿关节炎中2期试验ACR20应答系统性高估后续3期结果(OR 1.39,95%CI 1.25-1.57,P<0.001)。
- 银屑病关节炎2期与3期ACR20差异相似但无统计学意义(OR 1.35,95%CI 0.94-1.94,P=0.09)。
- 纳入标准差异 largely 解释观察到的疗效差异。
研究设计与样本
- 系统荟萃分析纳入所有研究靶向改善病情抗风湿药的随机双盲对照试验。
- 采用混合模型逻辑回归比较ACR20主要结局,并探索疗效高估的潜在决定因素。
主要发现
- 类风湿关节炎2期试验ACR20应答系统性高估3期结果(OR 1.39,95%CI 1.25-1.57,P<0.001)。
- 银屑病关节炎2期与3期ACR20差异相似但无统计学意义(OR 1.35,95%CI 0.94-1.94,P=0.09)。
- 纳入标准差异 largely 解释观察到的疗效差异。
关键数值与推荐
- 类风湿关节炎:2期与3期ACR20比较OR 1.39(95%CI 1.25-1.57,P<0.001)。
- 银屑病关节炎:2期与3期ACR20比较OR 1.35(95%CI 0.94-1.94,P=0.09)。
临床怎么用
- 解读2期风湿病试验阳性结果时需警惕对3期疗效的系统性高估。
- 关注2期与3期纳入标准差异对疗效外推的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Phase 3 trials are the mainstay of drug development across medicine but have often not met expectations set by preceding phase 2 studies. A systematic meta-analysis evaluated all randomized controlled, double-blind trials investigating targeted disease-modifying anti-rheumatic drugs in rheumatoid and psoriatic arthritis. Primary outcomes of American College of Rheumatology (ACR) 20 responses were compared by mixed-model logistic regression, including exploration of potential determinants of efficacy overestimation. In rheumatoid arthritis, phase 2 trial outcomes systematically overestimated subsequent phase 3 results (odds ratio comparing ACR20 in phase 2 versus phase 3: 1.39, 95% confidence interval: 1.25-1.57, P < 0.001). Data for psoriatic arthritis trials were similar, but not statistically significant (odds ratio comparing ACR20 in phase 2 versus phase 3: 1.35, 95% confidence interval: 0.94-1.94, P = 0.09). Differences in inclusion criteria largely explained the observed differences in efficacy findings. Our findings have implications for all stakeholders in new therapeutic development and testing, as well as potential ethical implications.
引用
- Kerschbaumer A, Smolen JS, Herkner H, et al. Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. Nat Med. 2020. PMID: 32313250. doi:10.1038/s41591-020-0833-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。